# A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

> **NCT00381602** · PHASE2 · TERMINATED · sponsor: **QLT Inc.** · enrollment: 3 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** GHRP-1/AG 70 mg depot in ESRD
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00381602
- **Lead sponsor:** QLT Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Lack of enrolment
- **Last updated:** 2011-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381602, "A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00381602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*